Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             72 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A framework for global surveillance of antibiotic resistance Grundmann, Hajo
 2011
 33-35 2 p. 79-87
9 p.
 artikel
2 Altered binding of chloroquine to ferriprotoporphyrin IX is the basis for chloroquine resistance Raynes, Kaylene J.
 1999
 33-35 2 p. 97-103
7 p.
 artikel
3 Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition Azucena, Eduardo
 2001
 33-35 2 p. 106-117
12 p.
 artikel
4 Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons Hall, Ruth M.
 1998
 33-35 2 p. 109-119
11 p.
 artikel
5 Antifungal combination therapy: where we stand Sugar, Alan M.
 1998
 33-35 2 p. 89-92
4 p.
 artikel
6 Antimicrobial peptides from platelets Yeaman, Michael R.
 1999
 33-35 2 p. 116-126
11 p.
 artikel
7 Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Eichhorn, Martin E
 2004
 33-35 2 p. 125-138
14 p.
 artikel
8 Apoptin-induced apoptosis: potential for antitumor therapy Noteborn, Mathieu H.M.
 1998
 33-35 2 p. 99-103
5 p.
 artikel
9 Apoptosis is critical for drug response in vivo Schmitt, Clemens A.
 2001
 33-35 2 p. 132-134
3 p.
 artikel
10 Apoptosis: mediator or mode of cell killing by anticancer agents? Brown, J.Martin
 2001
 33-35 2 p. 135-136
2 p.
 artikel
11 ATP-binding cassette transporters: from multidrug resistance to genetic disease, Gosau, Austria, 20–27 February 1999 Dey, Saibal
 1999
 33-35 2 p. 130-133
4 p.
 artikel
12 b-Lactamase inhibitors Page, Malcolm G.P.
 2000
 33-35 2 p. 109-125
17 p.
 artikel
13 Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective Mouton, Johan W.
 2011
 33-35 2 p. 107-117
11 p.
 artikel
14 Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now Freire-Moran, Laura
 2011
 33-35 2 p. 118-124
7 p.
 artikel
15 Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents Meijer, Laurent
 2000
 33-35 2 p. 83-88
6 p.
 artikel
16 Definitive proof for a role of pfmdr 1 in quinoline resistance in Plasmodium falciparum Ward, S.A.
 2000
 33-35 2 p. 80-81
2 p.
 artikel
17 Diagnostics as essential tools for containing antibacterial resistance Okeke, Iruka N.
 2011
 33-35 2 p. 95-106
12 p.
 artikel
18 Different cell thresholds for commitment to death: a link between carcinogenesis and drug resistance Hickman, John A.
 1998
 33-35 2 p. 84-85
2 p.
 artikel
19 Does resistance to apoptosis affect clinical response to antitumor drugs? Borst, Piet
 2001
 33-35 2 p. 129-131
3 p.
 artikel
20 Editorial Board 2003
 33-35 2 p. i-
1 p.
 artikel
21 Editorial Board 2004
 33-35 2 p. i-
1 p.
 artikel
22 Editorial Board 2011
 33-35 2 p. i-
1 p.
 artikel
23 Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children Esposito, Susanna
 2002
 33-35 2 p. 73-87
15 p.
 artikel
24 Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Shankar, Sharmila
 2004
 33-35 2 p. 139-156
18 p.
 artikel
25 Erratum 2001
 33-35 2 p. 139-
1 p.
 artikel
26 Erratum 1998
 33-35 2 p. 155-
1 p.
 artikel
27 Evolution of the serine β-lactamases: past, present and future Hall, Barry G
 2004
 33-35 2 p. 111-123
13 p.
 artikel
28 Fighting bacterial infections—Future treatment options Fernebro, Jenny
 2011
 33-35 2 p. 125-139
15 p.
 artikel
29 HIV resistance to antiviral drugs: public health implications Wainberg, Mark A.
 1998
 33-35 2 p. 104-108
5 p.
 artikel
30 HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Miller, Michael D
 2004
 33-35 2 p. 89-95
7 p.
 artikel
31 HIV resistance to zidovudine: the role of pyrophosphorolysis Arion, Dominique
 1999
 33-35 2 p. 91-95
5 p.
 artikel
32 Introduction 2011
 33-35 2 p. 67-
1 p.
 artikel
33 Lamivudine resistance in hepatitis B: mechanisms and clinical implications Fischer, Karl P
 2001
 33-35 2 p. 118-128
11 p.
 artikel
34 Literature highlights: recent research 000 in infectious disease drug resistance 2004
 33-35 2 p. 157-158
2 p.
 artikel
35 Low-level antibacterial resistance: a gateway to clinical resistance Baquero, Fernando
 2001
 33-35 2 p. 93-105
13 p.
 artikel
36 Mechanisms of isoniazid resistance in Mycobacterium tuberculosis Barry III, Clifton E.
 1998
 33-35 2 p. 128-134
7 p.
 artikel
37 Meetings Calendar 1999
 33-35 2 p. 135-138
4 p.
 artikel
38 Meetings Calendar 2003
 33-35 2 p. 109-110
2 p.
 artikel
39 Meetings Calendar 2002
 33-35 2 p. 115-117
3 p.
 artikel
40 MEETINGS CALENDAR 2000
 33-35 2 p. 127-131
5 p.
 artikel
41 Meetings calendar 1998
 33-35 2 p. 153-154
2 p.
 artikel
42 Mitochondria as targets for established and novel anti-cancer agents Grad, Jennifer M.
 2001
 33-35 2 p. 85-91
7 p.
 artikel
43 Molecular Approaches to Malaria 2000 Cowman, Alan F.
 2000
 33-35 2 p. 74-76
3 p.
 artikel
44 Molecular targets and cancer therapeutics: discovery, development and clinical validation Teicher, Beverly A.
 2000
 33-35 2 p. 67-73
7 p.
 artikel
45 Multidrug ABC transporters from bacteria to man: an emerging hypothesis for the universality of molecular mechanism and function Hrycyna, Christine A.
 1998
 33-35 2 p. 81-83
3 p.
 artikel
46 Multidrug resistance: can different keys open the same lock? Kaur, Parjit
 2002
 33-35 2 p. 61-64
4 p.
 artikel
47 Neovascularization: the Achilles' heel of tumors? Voest, Emile E.
 1998
 33-35 2 p. 86-87
2 p.
 artikel
48 New cancer therapeutics: target-specific in, cytotoxics out? Broxterman, Henk J
 2004
 33-35 2 p. 79-87
9 p.
 artikel
49 Pharmacogenomics of ABC transporters and its role in cancer chemotherapy Sparreboom, Alex
 2003
 33-35 2 p. 71-84
14 p.
 artikel
50 Positive and negative regulation of cellular sensitivity to anti-cancer drugs by FGF-2 Coleman, Aaron B.
 2003
 33-35 2 p. 85-94
10 p.
 artikel
51 Recent developments in HIV-1 drug resistance Kuritzkes, Daniel R.
 1999
 33-35 2 p. 127-129
3 p.
 artikel
52 Regulation of MDR1 gene expression: emerging concepts Kantharidis, Phillip
 2000
 33-35 2 p. 99-108
10 p.
 artikel
53 Resistance as a tool in the study of old and new drug targets in Toxoplasma McFadden, Diane C
 2001
 33-35 2 p. 79-84
6 p.
 artikel
54 Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms Gilbert, Christian
 2002
 33-35 2 p. 88-114
27 p.
 artikel
55 ROS stress in cancer cells and therapeutic implications Pelicano, Helene
 2004
 33-35 2 p. 97-110
14 p.
 artikel
56 Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions Zaffaroni, Nadia
 2002
 33-35 2 p. 65-72
8 p.
 artikel
57 Targeting farnesyltransferase: is Ras relevant? Prendergast, George C.
 1999
 33-35 2 p. 81-84
4 p.
 artikel
58 Telomerase targeting in cancer treatment: new developments Helder, Marco N.
 1999
 33-35 2 p. 104-115
12 p.
 artikel
59 89th Annual Meeting of the American Association for Cancer research (AACR) Broxterman, Henk J.
 1998
 33-35 2 p. 151-152
2 p.
 artikel
60 The global need for effective antibiotics—A summary of plenary presentations Alvan, Gunnar
 2011
 33-35 2 p. 70-76
7 p.
 artikel
61 The global need for effective antibiotics—Moving towards concerted action Cars, Otto
 2011
 33-35 2 p. 68-69
2 p.
 artikel
62 The influence of glutathione metabolism on multidrug resistance in MRP-overexpressing cells Twentyman, Peter
 1998
 33-35 2 p. 121-127
7 p.
 artikel
63 The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery Alaoui-Jamali, Moulay A.
 2003
 33-35 2 p. 95-107
13 p.
 artikel
64 The role of CD95 system in chemotherapy Debatin, Klaus-Michael
 1999
 33-35 2 p. 85-90
6 p.
 artikel
65 The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access? Nikaido, Hiroshi
 1998
 33-35 2 p. 93-98
6 p.
 artikel
66 The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance Bergström, Richard
 2011
 33-35 2 p. 77-78
2 p.
 artikel
67 The TRAIL to an anti-cancer agent El-Deiry, Wafik S.
 1999
 33-35 2 p. 79-80
2 p.
 artikel
68 Towards new business models for R&D for novel antibiotics So, A.D.
 2011
 33-35 2 p. 88-94
7 p.
 artikel
69 Transfer of drug resistance genes in hematopoietic progenitors for chemoprotection: is it still an option? Laufs, S.
 2003
 33-35 2 p. 57-69
13 p.
 artikel
70 Treatment strategies for Aspergillus infections Chiller, Tom M.
 2000
 33-35 2 p. 89-97
9 p.
 artikel
71 Turning p53 on or off: either way may treat cancer Fisher, David E.
 2000
 33-35 2 p. 77-79
3 p.
 artikel
72 Vancomycin resistance in staphylococci Hiramatsu, Keiichi
 1998
 33-35 2 p. 135-150
16 p.
 artikel
                             72 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland